Duchenne Muscular Dystrophy

Duchenne muscular dystrophy or DMD is the most common of the muscular dystrophies, affecting approximately 1 in every 3,500 newborn boys. It is caused by a fault in a gene called the dystrophin or DMD gene. A fault in this gene stops the body making a protein called dystrophin. This protein is important in muscle fibres, and its absence results in muscle weakness that gets worse over time because muscle cells break down and are gradually lost.
Because the dystrophin gene is on the X chromosome, Duchenne muscular dystrophy affects only boys. Girls have two X chromosomes, so if one of these is unaffected it can usually compensate for the faulty one, while boys have one X and one Y chromosome, so if their single copy of the dystrophin gene is faulty, they have the symptoms of DMD, while girls with one affected gene and one normal one usually won’t show symptoms but can be “carriers”. This means that the disease can be passed on in families – a mother who is a carrier has a 50:50 chance of having a son who is affected. But in up to about a third of cases, the mutation arises spontaneously in the boy.
Contents:
- Family Guides
- Clinical Trials
- Registries for DMD
- Patient Organisations
- Meetings & Events
- Research Overview
- Publications
- Standards of Care
- Resources for Researchers
- Animal Model Choice for DMD
Clinical Trials
- Follow-up Study on Female Carriers With DMD Gene Variants
- Duchenne Muscular Dystrophy Video Assessment Registry
- AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
- A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.
- Trunk Oriented Exercises Versus Whole-body Vibration for Duchenne Muscular Dystrophy
- AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Boys With DMD
- Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping
- Neuropsychological Profiles of Children With Duchenne Muscular Dystrophy and Its Effects on Motor Functions
- Evaluation of Home Based Assessments on Participants With DMD
- Physical Activity Level and Cognitive Functions in Children With Duchenne Muscular Dystrophy
- Treatment of Myotonia - Lamotrigine Versus Namuscla
- Motor Imagery on Children With DMD on Gait and Balance Functions
- Dual Task in Duchenne Muscular Dystrophy
- Quality and Independence of Gait Classification Scale for DMD (QIGS-DMD)
- Investigation of the Validity and Reliability of the Kinesthetic and Visual Imagery Questionnaire in Children With Duchenne Muscular Dystrophy
- Natural History of Duchenne Muscular Dystrophy Cardiomyopathy (DMD-CMP)
- Cultural Adaptation, Validity, and Reliability of the Turkish Version of North Star Ambulatory Assessment
- A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy
- Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
- E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home"
Registries for Duchenne Muscular Dystrophy
Argentina

Armenia

Australia

Austria

Belgium

Brazil

Bulgaria

Canada (English)

China

China

China

China

Colombia

Croatia

Czech Republic

Denmark

Egypt

Egypt

Finland

France

Georgia

Germany

Hungary

India

Iran

Israel

Italy

Japan

Korea

Latvia

Lebanon

Lithuania

North Macedonia

Mexico

Netherlands

New Zealand

Pakistan

Peru

Poland

Romania

Serbia

Slovenia

English
Spain

Spain

Sudan

Sweden

Switzerland

Turkey

Turkey

Turkey

Ukraine

United States

Venezuela

Patient organisations
Action Duchenne – United Kingdom


































Meetings and events


Event: 3rd International FAIR Data ‘Visiting’ For Duchenne & Other Rare Diseases
Start Date: November 22, 2022
Location: online

Event: 3rd Symposium on Muscle-Bone interaction in Duchenne Muscular Dystrophy
Start Date: November 7, 2022
Location: Online


Research Overview
The aim of this overview is to inform patients and parents about the different therapeutic approaches for Duchenne muscular dystrophy currently under investigation, to describe the advantages and disadvantages of each approach and to list the hurdles that have to be overcome before these approaches can be applied to patients.
Find out more about what is currently happening in research >>

Registry Publications - Summary Articles
The importance of genetic diagnosis for Duchenne muscular dystrophy
Published : January, 2016
Recent developments in the management of Duchenne muscular dystrophy
Published : October, 2015
Adult care for Duchenne muscular dystrophy in the UK
Published : December, 2014
The burden of Duchenne muscular dystrophy
Published : August, 2014
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
Published : February, 2010
Standards of Care
Part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
Part 2: Respiratory, cardiac, bone health, and orthopaedic management
Part 3: Primary care, emergency management, psychosocial care, and transitions of care across the lifespan
Resources for researchers
To find out more please click here.
Animal model choice for DMD
The currently used mammalian models for DMD include several mice strains, two dog models and one cat model. The characteristics of each phenotype and pathology have been analyzed and compared in detail.